Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML study group Ulm

Blood

Volumn 100, Issue 13, 2002, Pages 4372-4380

  Fröhling, Stefan ^a,b   Schlenk, Richard F ^a,b   Breitruck, Jochen ^a,b   Benner, Axel ^a,b   Kreitmeier, Sylvia ^a,b   Tobis, Karen ^a,b   Döhner, Hartmut ^a,b   Döhner, Konstanze ^a,b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CD135 ANTIGEN; CYTARABINE; LACTATE DEHYDROGENASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELISM; ARTICLE; BLAST CELL; BLOOD CELL; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DRUG MEGADOSE; FEMALE; GENE DELETION; GENE DUPLICATION; GENE MUTATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

EID: 0037114829     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1440     Document Type: Article

References (60)

1. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subgroup. Cancer Res. 1998;58:4173-4179.
2. Döhner H, Fischer K, del Valle F, et al. Stratification of postremission therapy in adult acute myeloid leukemia according to the karyotype: First results of the AML HD93 multicenter treatment trial [abstract]. Blood. 1997;90:584.
3. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
4. Mrózek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Baillieres Best Pract Res Clin Haematol. 2001;14:19-47.
5. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of pre-remission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075-4083.
6. Caligiuri MA, Strout MP, Lawrence D, et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res. 1998;58:55-59.
7. Döhner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm (AMLSG ULM). J Clin Oncol. 2002;20:3254-3261.
8. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000;14:796-804.
9. Lyman SD, Jacobsen SE. c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood. 1998;91:1101-1134.
10. McKenna HJ, Stocking KL, Miller RE, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. 2000;95:3489-3497.
11. Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature. 1994;368:643-648.
12. Lyman SD, James L, Zappone J, Sleath PR, Beckmann MP, Bird T. Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene. Oncogene. 1993;8:815-822.
13. Lisovsky M, Estrov Z, Zhang X, et al. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: Regulation of Bcl-2 and Bax. Blood. 1996;88:3987-3997.
14. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 1991;65:1143-1152.
15. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Genomic structure of human FLT3: Implications for mutational analysis. Br J Haematol. 2001;113:1076-1077.
16. Agnes F, Shamoon B, Dina C, Rosnet O, Birnbaum D, Galibert F. Genomic structure of the downstream part of the human FLT3 gene: Exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene. 1994;145:283-288.
17. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol. 2000;111:190-195.
18. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-3080.
19. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752-1759.
20. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911-1918.
21. Rombouts WJC, Blokland I, Löwenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 2000;14:675-683.
22. Rombouts WJ, Broyl A, Martens AC, Slater R, Ploemacher RE. Human acute myeloid leukemia cells with internal tandem duplications in the Flt3 gene show reduced proliferative ability in stroma supported long-term cultures. Leukemia. 1999;13:1071-1078.
23. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study. Cancer Res. 2001;61:7233-7239.
24. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: A study on a large series of patients and cell lines. Leukemia. 1997;11:1605-1609.
25. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89-94.
26. Fenski R, Flesch K, Serve S, et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol. 2000;108:322-330.
27. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-631.
28. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the ras and STAT5 pathways. Blood. 2000;96:3907-3914.
29. Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 2000;14:1766-1776.
30. Abu-Duhier FM, Goodeve AC, Wilson GA, Care IRS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol. 2001;113:983-988.
31. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439.
32. Kondo M, Horibe K, Takahashi Y, et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol. 1999;33:525-529.
33. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria of the classification of acute myeloid leukemia. Ann Intern Med. 1985;103:620-625.
34. Mitelman F. ISCN (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger; 1995.
35. Fischer K, Scholl C, Sàlat J, et al. Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia. Blood. 1996;88:3962-3971.
36. Fröhling S, Skelin S, Liebisch C, et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol. 2002;20:2480-2485.
37. Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia. 1997;11:1447-1452.
38. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
39. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986;5:255-260.
40. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
41. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
42. Cox DR. Regression models and life tables (with discussion). J R Stat Soc. 1972;34:187-220.
43. Ohno R, Kobayashi T, Tanimoto M, et al. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. Cancer. 1993;71:3888-3895.
44. Kobayashi T, Miyawaki S, Tanimoto M, et al. Randomized trials between behenoy) cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. J Clin Oncol. 1996;14:204-213.
45. Miyawaki S, Tanimoto M, Kobayashi T, et al. Randomized study of individualized induction therapy with or without etoposide in adult acute myeloid leukemia (except for M3) (JALSG-AML92 study and analysis of prognostic factors [abstract]. Blood. 1997;90:503.
46. Vellenga E, van Putten WLJ, Boogaerts MA, et al. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? Bone Marrow Transplant. 1999;23:1279-1282.
47. Löwenberg B, Boogaerts MA, Daenen SMGJ, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol. 1997;15:3496-3506.
48. Löwenberg B, Suciu S, Archimbaud E, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood. 1997;90:2952-2961.
49. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia: Results of the Medical Research Council's 10th AML trial (MRC AML 10). Blood. 1997;89:2311-2318.
50. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896-903.
51. Kolitz JE, George SL, Hurd D, et al. Cytogenetic risk-adapted intensification followed by immunotherapy with recombinant interleukin-2 (rlL-2) in patients (pts) <60 years old with acute myeloid leukemia (AML) in first complete remission (CR): Preliminary results of CALGB 9621 [abstract]. Blood. 1999;94:579.
52. Büchner T, Hiddemann W, Schaefer UW, et al. Combined effect of very early intensification and prolonged postremission chemotherapy in patients with AML. Leukemia. 1992;5:68-70.
53. Boissel N, Cayuela JM, Fund X, et al. Double induction in acute myeloid leukemia (AML) with Flt3 gene internal tandem duplication [abstract]. Blood. 2000;96:316.
54. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood. 1996;87:4979-4989.
55. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 713 patients with acute myelogenous leukemia (AML): High prevalence in FAB-subtype M5 and identification of subgroups with poor prognosis [abstract]. Blood. 2001;98:717.
56. Thiagalingam S, Laken S, Willson JKV, et al. Mechanisms underlying losses of heterozygosity in human colorectal cancers. Proc Natl Acad Sci U S A. 2001;98:2698-2702.
57. Stirewalt DL, Willman CL, Radich JP. Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific. Leuk Res. 2001;25:1085-1088.
58. Karp JE, Stopeck A, Albitar M, et al. Phase II clinical-laboratory of the anti-angiogenesis receptor tyrosine kinase (RTK) inhibitor SU5416 in refractory acute myelogenous leukemia and myelodysplasia (MDS) [abstract]. Blood. 2001;98:495.
59. Mesters RM, Padro T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood. 2001;98:241-243.
60. O'Farrell AM, Abrams T, Yuen H, et al. SUGEN compounds SU5416 and SU11248 inhibit Flt3 activity: Therapeutic application in AML [abstract]. Blood. 2001;98:497.